Capital expenditure expected to moderate to Rs. 5.6 billion in FY2025 from an estimated Rs. 7.6 billion in FY2024
European markets now contribute 51% of our business revenue up from 43% in Q4 FY24 and 34% in Q1 FY24
Third approval in China for AstraZeneca and Daiichi Sankyo’s Enhertu in less than two years
Morepen Labs successfully raised Rs. 200 Crore through QIP
For the 2024 outlook, sales growth is now expected to be 22-28% at CER
Q1FY25 Revenue from Operations grew by 15% to Rs. 177 crore
Our centers are performing as expected or even better
The campaign targets 63 endemic districts across Bihar, Jharkhand, Karnataka, Odisha, Telangana, and Uttar Pradesh
CN201 is a next generation CD3xCD19 bispecific antibody that augments and diversifies Merck’s pipeline, with potential applications in B-cell malignancies and autoimmune diseases
Revenue from Operations increased by 10.5% YoY to Rs. 7,567 crore with growth across the businesses
Subscribe To Our Newsletter & Stay Updated
